Cannabis-based Finished Drug Development
Speed and confidence through deep partnerships
Explore our
clinical research areas
Our diversified research & development strategy
We develop Cannabis-based finished drugs for rare diseases.
We develop Cannabis-based therapy solutions for women.
We focus on Orphan indications, because…
Orphan indications, which encompass rare diseases or conditions often overlooked by major pharmaceutical companies due to limited commercial viability, tend to have fewer available therapies, leaving patients with limited treatment options. In this landscape, cannabis emerges as a promising avenue with the potential to significantly enhance the quality of life for patients affected by these conditions.
The unique pharmacological properties of cannabis, particularly its diverse array of cannabinoids and their interaction with the endocannabinoid system, offer a novel and potentially effective therapeutic approach for managing symptoms in many of these neglected conditions. The multi-target effects of cannabinoids on various physiological pathways, coupled with their relatively favorable safety profile, present a compelling opportunity to address the unmet needs of patients.
We focus on female health, because…
The female reproductive system is notably rich in endocannabinoid receptors, highlighting the important role of the endocannabinoid system and the physiological functions specific to female health.
The interplay between cannabinoids and the endocannabinoid system within the female reproductive system presents an area of high potential for therapeutic intervention.
With its ability to modulate various biological processes, including for example hormonal regulation, menstrual health, fertility, and menopause, cannabis-based therapies offer a promising and novel avenue for improving women’s health and well-being.
IP protection from
the genetics
In line with our “From Plant to Patient” approach, we develop our finished drugs starting from the genetics. We develop unique cultivars that reflect the specific therapeutic needs of our indications under research. This gives us a very strong, non-replicable starting point for IP secure finished drug development.
Third party
clinical R&D servicing
We offer our R&D platform to enable the drug development of third party pharmaceutical companies.
We engage our expertise, partners and network to accelerate your drug development process.
Our R&D platform approach
Cannaflos has build sustainable partnerships that enable clinical research for Cannabis based medicines. Either through selective shareholder participation or value-based B2B partnership, we are curating an ecosystem of key players in phytomedicine, CRO, patient and market access, IP management and regulatory .
This network of partners enables us to accelerate our clinical trails, while maintaining the highest performance standards.
Recognizing the complexity of the endocannabinoid system and respecting individual differences is crucial in designing clinical trials. This approach holds the key to successful trials, ultimately advancing patient care and outcomes.
Meike Meinzer
Head of Drug Development
Biologist with focus on phytomedicine
Expert cannabinoids and their therapeutic use
Scientific and clinical conceptualisation
Medicinal chemistry is all about understanding and optimizing the basic chemical principles under which medicines act on our body. Understanding the structural and functional features of the endocannabinoid system and the diverse factors that dictate the metabolic output of the Cannabis plant enables the possibility to develop new promising Cannabis-based medications.
Dr. Yesid Ramirez
Head of Scientific Operations
Chemist with emphasis in biochemistry
Ph.D. in medicinal chemistry and drug design
Over 10 years of experience in the use of cannabis and cannabinoids as therapeutic agents
Explore our
clinical research areas
Our diversified research & development strategy
We develop Cannabis-based finished drugs for rare diseases.
We develop Cannabis-based therapy solutions for women.
